BPC-157: What the Research Shows

BPC-157 is the most talked-about peptide in the injury-recovery world and one of the least tested in people. That sentence is the whole page. Everything below is the detail behind it.

We are not going to tell you BPC-157 works, and we are not going to tell you it does not. We are going to tell you what has been measured, in what species, by whom, and what the US government currently says about selling it. Where we could not verify something, we say so and leave it unverified rather than filling the hole with a number that sounds right.

What BPC-157 is

BPC stands for body protection compound. The 157 is a serial designation for this particular sequence, not a dose, a strength or a generation number. That naming is standard in the peer-reviewed literature rather than a vendor invention - the review cited throughout this page carries the phrase in its own title (Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab)).

Read the name as a label, not as a finding. “Body protection” describes what the compound was named for by the researchers who named it. It is not a description of anything demonstrated in a human being, and no part of this page rests on it.

BPC-157 itself is a synthetic pentadecapeptide - a chain of fifteen amino acids (Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab)).

That is close to all we are willing to state flatly about its composition, and the restraint is deliberate. The amino-acid sequence, the CAS numbers and the story that BPC-157 is a fragment of a larger body protection compound found in human gastric juice are repeated everywhere. When we tried to trace them to a primary regulatory document that we could quote, the attribution did not survive checking, so we do not reproduce them here. We have no reason to think the sequence is wrong. But “everyone says so” is not a source, and we would rather show you the seam than paper over it.

The origin claim deserves separate scepticism, and it is a different question from the naming. What the letters stand for is settled. Whether the parent protein those letters name - the “BPC” that BPC-157 is supposedly a fragment of - has ever been independently isolated, sequenced and characterised is not. We are not saying it has not been. We could not confirm it either way, and neither should anyone selling you a vial.

The evidence

Start with the cleanest fact available. On 15 July 2026, a PubMed search for ("BPC 157" OR "BPC-157") AND clinical trial[pt] returned zero records. The same search restricted to the randomised-controlled-trial publication type also returned zero. Broadening it - adding controlled clinical trial, clinical trial protocol and phase I publication types, and the synonyms BPC157, “body protection compound” and “pentadecapeptide BPC 157” - still returned zero.

State that result carefully: no BPC-157 study is indexed in PubMed under a clinical-trial or RCT publication type, and that is strong but not absolute evidence against the existence of human trials, since publication-type tagging can lag and a non-indexed or untagged trial would not appear.

Against that zero sits a literature of 222 PubMed records, the great majority animal work - 156 carry the Animals index term and 112 carry Rats. Each of those figures comes from its own separate query; the linked search supports only the zero-count for the clinical-trial publication type. The most telling number is a cross-tabulation: 50 records are indexed to humans, but humans[mh] NOT animals[mh] returns zero. Every human-indexed record in the BPC-157 literature is also indexed to animals - there is no record in that set that PubMed tags as human work and nothing else.

Review literature reaches the same place from a different direction: the majority of studies were performed in small rodent models, and efficacy is yet to be confirmed in humans (Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab)).

The human record is not empty - it is small and it is null

An indexing result is evidence about tagging, not about the world, so do not stop there. The FDA’s briefing document for the July 2026 advisory committee meeting inventories the complete published human experience with BPC-157, and it comes to five studies and roughly eighty people: a phase 1 rectal enema study in healthy volunteers, with twenty-four dosed; one randomised placebo-controlled trial, fifty-three patients, an enema against placebo for two weeks in ulcerative colitis; the retrospective knee-pain review above; a single-arm study in twelve people with interstitial cystitis; and a report of two people dosed intravenously.

That single randomised trial is the only controlled test of BPC-157 in people that exists, and on its own numbers it did not find a benefit. Disease-activity scores fell further on BPC-157 than on placebo, but the between-group difference carried a confidence interval that crossed zero - a result compatible with no effect at all. It has never appeared as anything more than a meeting abstract, so it cannot be read in full.

Hold both halves of that. BPC-157 is not a compound nobody has ever given to a human. It is a compound that has been given to about eighty humans, once under controlled conditions, in a trial too small to settle anything, which came back null and was never fully published. That is a worse position than “untested” in one respect: the only time anyone checked, the answer was no.

Where the literature comes from

Now the part most articles leave out. Of the 222 PubMed records on BPC-157, 175 list either Sikiric P or Seiwerth S of the University of Zagreb as an author - 79%. Per-author tallies run Seiwerth 162, Sikiric 156, Drmic 66, Skrtic 49.

Be careful about what this does and does not mean, because the same statistic gets weaponised in both directions. It does not mean the work is wrong - a small group can be productive because it built a field. It does not mean there is no independent literature: 47 records exist without either name on them, which is not nothing.

What it does mean is that the evidence base is not the thing people picture when they hear “hundreds of studies”. Hundreds of studies from many independent groups converging on one answer is powerful. A few hundred where roughly four in five come from one department is a different object - one where a shared method, assay, animal model or assumption can propagate through the whole corpus without anyone outside noticing. That is not an accusation. It is a reason to want replication before belief, and after thirty years the replication that would settle it has not arrived. Whether that reflects a funding and interest gap or a replication problem, the literature by itself cannot tell you.

Mechanisms, in plain English

The mechanistic story in marketing copy usually involves angiogenesis - the growth of new blood vessels - and nitric oxide. There is real work behind it, and it is worth understanding both what it shows and what it cannot show.

The clearest example is Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. (opens PubMed in a new tab), from an independent Taiwanese group. In chick chorioallantoic membrane and endothelial tube-formation assays, they reported increased vessel density; in rats with induced hind-limb ischaemia, accelerated blood-flow recovery. In cultured human vascular endothelial cells, BPC-157 increased VEGFR2 messenger RNA and protein - but not VEGF-A itself. Blocking receptor internalisation with dynasore blocked the effect, and the authors reported time-dependent activation of the VEGFR2–Akt–eNOS pathway.

Translated: researchers propose that BPC-157 acts on the receptor for vascular endothelial growth factor rather than on the growth factor itself, and that this activation drives a signalling cascade ending in nitric oxide production, which supports new vessel formation and blood flow. Review literature describes the reported mechanism in the same terms - nitric oxide synthase, dopamine regulation and VEGF receptor pathways (Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). (opens PubMed in a new tab)). That is a coherent, testable proposal.

It is also, in this work, entirely animal and in vitro. There is no human in vivo data in it. A mechanism observed in a dish is a hypothesis about people, not a finding about them.

Pharmacokinetics

The half-life of BPC-157 in humans is not established.

We state that flatly because it is the single most abused fact about this compound. Search for a dosing protocol and you will find confident half-life figures in minutes, and dosing intervals derived from them. Those numbers trace back to rodent studies or to secondary sources we could not follow to a primary measurement. We will not repeat them here, because repeating an unverified number is how it becomes true.

We could not find a primary source establishing human pharmacokinetics for BPC-157 - no absorption, distribution, clearance or half-life figure we were able to verify. We are reporting the limit of our own search, not a proof of absence; but if a human PK study exists, neither we nor the sellers quoting half-lives at you have produced it.

The claim that BPC-157 resists degradation in human gastric juice for over 24 hours is likewise something we could not verify, and it originates predominantly from the Zagreb group’s own literature. Gastric stability, even if real, would not by itself establish oral absorption - surviving the stomach and crossing into the blood are two different problems.

Safety: what is known and what is not

What is known fits in a paragraph, and most of it is a statement about missing information rather than about hazard.

Reviews report few adverse reactions and no achieved lethal dose (Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab)) - but that is animal data, and absence of reported harm in rodents is not evidence of safety in people. There is no long-term human safety data at all.

The FDA’s own stated concern, set out on its page listing bulk drug substances that may present significant safety risks, is that compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration”, may have “complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization”, and that the agency “has identified no, or only limited, safety-related information for the proposed routes of administration”, so “the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”

That last clause is the honest summary of the safety position, and it is the agency’s own.

A theoretical concern is worth naming honestly. If BPC-157 is pro-angiogenic - and the animal and in vitro work suggests it is - a reasonable person might ask whether promoting blood-vessel growth could also support tissue you would not want supported, such as a tumour. The status of that concern: it is an inference, not a finding. We could not find work testing it in either direction. It is a question the evidence base has not answered, which differs from a risk the evidence base has documented. Anyone telling you BPC-157 is proven safe on this point, or proven dangerous on it, is going beyond what exists.

One more unknown dwarfs the pharmacology: nobody has established what is actually in the products people buy. The FDA flagged API characterisation and peptide-related impurities as unresolved, and salts and derivatives are sold under the same common name. Peptide-related impurities are structurally similar to the target peptide and hard to identify without sophisticated analytics. We found no independent assay data on marketed research-use-only product. So even the rodent literature may not describe the substance in the vial.

US legal status, precisely

Review literature puts the baseline plainly: BPC-157 has not been approved for use in standard medicine by the FDA or other global regulatory authorities, on the stated grounds that comprehensive clinical studies confirming health benefits in humans are absent (Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). (opens PubMed in a new tab)).

The 503A compounding question

Section 503A of the Federal Food, Drug, and Cosmetic Act lets a compounding pharmacy make a drug for an individual patient. Under section 503A(b)(1)(A)(i), a bulk drug substance may be used in compounding only if it complies with an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A Bulks List.

In its briefing document for the 23–24 July 2026 Pharmacy Compounding Advisory Committee meeting, the FDA states that “There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for BPC-157 (free base) or its acetate form, and neither is a component of an FDA-approved drug” (Section I, Introduction, p. 8). It is also not on the Bulks List, and the FDA proposes not adding it. BPC-157 therefore satisfies none of the three conditions and is not presently eligible for lawful 503A compounding.

Three qualifications matter, and most coverage drops all three.

First, the missing monograph is background framing, not the FDA’s stated basis for its proposal. The agency’s reasoning (Section III, pp. 44–47) rests on inadequate physicochemical characterisation, inconsistent naming conventions, lack of safety and immunogenicity data, insufficient evidence of effectiveness for ulcerative colitis, and the availability of FDA-approved drugs for that condition. Note the indication: the sole use the FDA evaluated is ulcerative colitis - not tendon, joint or injury healing.

Second, this is a pre-meeting staff proposal, not a final agency determination. The FDA says it will not issue a final determination until advisory committee input is considered, and committee recommendations are non-binding in any case. The underlying nominations - from Wells Pharmacy Network, and from LDT Health Solutions with the International Peptide Society - were withdrawn, and the FDA is evaluating the substances at its own discretion.

Third, a fine point on the “Category 2” claim you will see everywhere. Under the FDA’s interim policy, “category 2” holds nominated bulk drug substances for which the agency “identified potential significant safety risks”. BPC-157 was added to Category 2 on 29 September 2023 - archived snapshots of the agency’s page preserve that row verbatim. But on the current page, BPC-157 no longer appears in the Category 2 table at all. It sits in a separate table headed “Bulk drug substances nominated but withdrawn”, which the FDA defines as substances “previously in category 2 of the interim policies [that] were withdrawn by the nominators”. You cannot read a current Category 2 enforcement posture for BPC-157 off that page. The enforcement language people quote is not on it either - that lives in a separate guidance, the Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A, under which the FDA does not intend to apply the category 1 enforcement policy to category 2 substances and “would consider taking action against a compounder for compounding drug products with this bulk drug substance under its general enforcement policies”. Category 2 is an interim-policy listing published on the FDA’s website, not a codified rule. Whether the move to “withdrawn” had operative legal effect or is bookkeeping is a question for counsel; the 503A eligibility analysis above appears unchanged either way.

One more data point: a full-text search of the Federal Register for “BPC-157” returns exactly one document - the 16 April 2026 notice of the advisory committee meeting. Since additions to the 503A Bulks List happen by rulemaking, that is consistent with BPC-157 never having been added to the list. It is not evidence that a determination was withheld.

What “research use only” actually means

It means the seller has written four words on a label. It does not create a legal category that products live in.

The FDA classifies a product by its intended use, and reads websites, product-page claims and social media marketing as evidence of intent. In a warning letter to Summit Research Peptides (#695607) dated 10 December 2024, the agency put it plainly: “Despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’ evidence obtained from your websites establish that your products are intended to be drugs for human use.” The products are then treated as unapproved new drugs under section 201(g)(1). That letter concerned other peptides, not BPC-157 - we have not retrieved a warning letter naming a BPC-157 seller, and we will not claim one exists on secondary reporting. But the reasoning is the general rule, and it is why “research use only” protects a vendor’s paperwork rather than a buyer’s body.

Sport

BPC-157 is prohibited at all times - in and out of competition - under the World Anti-Doping Agency’s category S0, non-approved substances, the catch-all for substances with no current approval for human therapeutic use. It is named explicitly in the 2026 Prohibited List.

That is worth stating flatly because the published literature will tell you otherwise. Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). (opens PubMed in a new tab) states that BPC-157 “is not currently listed as banned by the WADA.” As of the 2026 list, that is wrong, and it is the kind of error that ends a career when an athlete relies on it. If you are a tested athlete, check the current WADA list yourself. Do not take a vendor’s word, do not take a review article’s word, and do not take ours.

We examined only the US federal picture. State-level status, and status outside the US, were not checked.

What we would need to change our minds

A published, adequately powered, placebo-controlled human trial with a real clinical endpoint, run by a group with no stake in the outcome. Nothing of that description has surfaced in thirty years. The closest anyone has come - a fifty-three patient enema trial in ulcerative colitis - was too small to settle the question, came back null, and never made it past a meeting abstract. Until something better reports, BPC-157 remains a compound with a genuinely interesting animal literature, a mechanistic hypothesis worth testing, no confirmed efficacy in humans for anything, no human pharmacokinetics we could verify, no long-term safety data, no lawful route to market for human use in the US, and an unverified supply chain.

That is not a verdict against it. It is a description of how little anybody knows.

We’re not listing a research vendor here. Nothing on this page suggests you should take BPC-157, and no vendor can lawfully sell it to you for human use.

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.

1. 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
2. 2.Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.StudyPMID 27847966
3. 3.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
4. 4.FDA briefing document for the Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026 - evaluation of BPC-157-related bulk drug substances- US Food and Drug Administrationregulatory
5. 5.FDA - July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (meeting page)- US Food and Drug Administrationregulatory
6. 6.FDA - Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (contains the "bulk drug substances nominated but withdrawn" table)- US Food and Drug Administrationregulatory
7. 7.Internet Archive snapshot (21 April 2026) of the FDA bulk drug substances safety-risks page, preserving the Category 2 row for BPC-157- Internet Archive, snapshot of the US Food and Drug Administrationregulatory
8. 8.FDA - Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance for industry)- US Food and Drug Administrationregulatory
9. 9.FDA warning letter to Summit Research Peptides (#695607, 10 December 2024)- US Food and Drug Administrationregulatory
10. 10.WADA 2026 Prohibited List - BPC-157 named under S0, non-approved substances (national-agency mirror)- World Anti-Doping Agency, mirrored by the Jamaica Anti-Doping Commissionregulatory
11. 11.NCBI E-utilities esearch - ("BPC 157" OR "BPC-157") AND clinical trial[pt], queried 15 July 2026, zero records- US National Library of Medicinedatabase
12. 12.NCBI E-utilities esearch - BPC-157 records co-authored by Sikiric P or Seiwerth S, author-concentration tally, queried 15 July 2026- US National Library of Medicinedatabase
13. 13.Therapeutic Goods (Poisons Standard - June 2026) Instrument 2026, the current Poisons Standard (SUSMP). BPC-157 is a Schedule 4 (prescription only) entry, and Appendix D, clause 5 - possession without authority is illegal.- Federal Register of Legislation, Australian Governmentstatute
14. 14.TGA - Unapproved therapeutic goods. Goods not on the ARTG have not been assessed by the TGA for safety, quality or effectiveness, and reach patients only through defined pathways such as the Special Access Scheme.- Therapeutic Goods Administration, Australian Governmentregulatory
15. 15.TGA - Notice of final decision to amend the current Poisons Standard, ACMS #43. Created the Schedule 4 and Appendix D, clause 5 entries for BPC-157, implemented 1 June 2024.- Therapeutic Goods Administration, Australian Governmentregulatory
16. 16.TGA - Notice of interim decisions, ACMS #43 (PDF). The delegate's reasons: BPC-157 is "an unapproved medicine with no registered products affected", and vendors marketing it "for research only" is given as a reason to schedule it.- Therapeutic Goods Administration, Australian Governmentregulatory

Keep reading

Related guides

All guides →

• bpc-157 benefitsBPC-157 Benefits: What the Research Has FoundBPC-157 has one of the largest healing literatures in animal research. What those studies found, how small the human record is, and how to read the gap.2 min readRead guide→
• cjc-1295CJC-1295: With DAC and Without DAC, ExplainedTwo molecules share one name and behave nothing alike. One has a published multi-day half-life, the other has no human PK study. Plus legal status and sport bans.1 min readRead guide→
• ipamorelinIpamorelin: What the Clinical Record ShowsIpamorelin is a growth hormone secretagogue that reached Phase 2 and stopped there. What the 1998 pharmacology found, and what the marketing leaves out.2 min readRead guide→
• tb-500TB-500: What It Is, and Why It Is Not Thymosin Beta-4TB-500 is a seven amino acid fragment, not the full protein people cite for it. What that changes about the evidence, plus legal status and the WADA ban.1 min readRead guide→
• bpc-157 vs tb-500BPC-157 vs TB-500: How the Two DifferTwo different molecules with different literatures, sold as one healing stack. Structure, human data, legal status and WADA bans, side by side.2 min readRead guide→
• melanotanMelanotan: What the Published Cases ShowMelanotan products are unapproved tanning peptides, and the published human record is mostly case reports of serious harm. What those cases describe.1 min readRead guide→